Developments in Transduction, Connectivity and AI/Machine Learning for Point-of-Care Testing

O’Sullivan, Shane; Ali, Zulfiqur; Jiang, Xiaoyi; Abdolvand, Reza; Ünlü, M. Selim; Silva, Hugo Plácido da; Baca, Justin T.; Kim, Brian N.; Scott, Simon M.; Sajid, Mohammed Imran; Moradian, Siamak; Mansoorzare, Hakhamanesh; Holzinger, Andreas

doi:10.3390/s19081917

Cited by 20 publications

(12 citation statements)

References 145 publications

(154 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Point‐of‐care testing (POCT) is well‐suitable for rapid identification of specific pathogens in the field 22 . Microfluidic chips and lateral flow test strips are widely used POCT for the detection of samples 23 .…”

Section: Discussionmentioning

confidence: 99%

Field applicable detection of hepatitis B virus using internal controlled duplex recombinase‐aided amplification assay and lateral flow dipstick assay

Bai

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is a widespread blood‐borne pathogen associated with the complication of liver cirrhosis and hepatocellular carcinoma, particularly in south‐east Asian and African countries where HBV is highly endemic and the budget and resources are limited. Therefore, simple, rapid, and portable field detection methods are crucial to efficiently control HBV infection. In this study, using heat‐treated DNA, we developed two‐field applicable detection assays for HBV based on recombinase‐aided amplification (RAA). One was an internal controlled duplex RAA assay using a portable real‐time fluorescence detection device, another was an instrument‐free visual observation assay using lateral flow dipsticks. The entire experimental time was greatly shortened to less than 40 minutes at 39.0°C. The sensitivities, specificities, and clinical performance of both assays were evaluated. Compared with quantitative polymerase chain reaction assay as a reference, our results demonstrated that the two RAA‐based assay obtained 97.18% and 95.77% of sensitivity, respectively, and the specificity was 100%, by testing a total of 157 serum samples with HBsAg positive. We conclude that the advantages of rapidity, simplicity, portability, and visualization of proposed two assays make them great potentials in point‐of‐care testing of HBV infection by untrained people in resource‐limited situations.

show abstract

Section: Discussionmentioning

confidence: 99%

Field applicable detection of hepatitis B virus using internal controlled duplex recombinase‐aided amplification assay and lateral flow dipstick assay

Bai

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The feasibility of POCT for sepsis-related biomarkers has clearly been demonstrated by the existing commercially available assays that are routinely used for biomarkers such as CRP, lactate and PCT. Research and development focusing on new methods and techniques with the aim of developing POCT devices is a highly active area [121]. Microfluidic devices that enable the miniaturisation of conventional analytical technologies to facilitate POCT is one area of interest, since it can allow the automation of complex fluidic processes [122].…”

Section: Point-of-care Testing (Poct) For Sepsismentioning

confidence: 99%

Biomarkers for Point-of-Care Diagnosis of Sepsis

2020

Self Cite

View full text Add to dashboard Cite

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In 2017, almost 50 million cases of sepsis were recorded worldwide and 11 million sepsis-related deaths were reported. Therefore, sepsis is the focus of intense research to better understand the complexities of sepsis response, particularly the twin underlying concepts of an initial hyper-immune response and a counter-immunological state of immunosuppression triggered by an invading pathogen. Diagnosis of sepsis remains a significant challenge. Prompt diagnosis is essential so that treatment can be instigated as early as possible to ensure the best outcome, as delay in treatment is associated with higher mortality. In order to address this diagnostic problem, use of a panel of biomarkers has been proposed as, due to the complexity of the sepsis response, no single marker is sufficient. This review provides background on the current understanding of sepsis in terms of its epidemiology, the evolution of the definition of sepsis, pathobiology and diagnosis and management. Candidate biomarkers of interest and how current and developing point-of-care testing approaches could be used to measure such biomarkers is discussed.

show abstract

“…The CEA POC reader could include WiFi or Blutetooth connectivity to enable Cloud-based information sharing between primary (General Practitioner office) or tertiary care (care homes) or low resource settings to a central secondary care site. 26 A low cost microfluidic element that incorporates an assay with CEA POC reader offering highly sensitive absorption measurements could be applicable in a variety of clinical contexts. Such applications could include low cost point-ofcare diagnosis of COVID-19 by detection of SARS-CoV-2 using a colorimetric loop-mediated isothermal amplification (LAMP) assay within a microfluidic device.…”

Section: Sepsis Poc Diagnostic With Cea Detectionmentioning

confidence: 99%